{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:02:02Z","timestamp":1782025322996,"version":"3.54.5"},"reference-count":81,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Buddhist Tzu Chi Medical Foundation","award":["TCMF-MP-110-03-01"],"award-info":[{"award-number":["TCMF-MP-110-03-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum toxin A (BoNT-A) intravesical injections have been used to treat patients with refractory functional bladder disorders such as overactive bladder (OAB) and interstitial cystitis\/bladder pain syndrome (IC\/BPS), but the risk of adverse events and the need for repeated injections continue to prevent widespread application of this treatment. Liposomes are vesicles that comprise concentric phospholipid layers and an aqueous core; their flexible compositions enable them to adsorb and fuse with cell membranes and to deliver drugs or proteins into cells. Therefore, liposomes have been considered as promising vehicles for the less invasive delivery of BoNT-A. In previous placebo-controlled trials including patients with OAB refractory to medical treatment, it was shown that liposomal BoNT-A could significantly decrease the frequency and urgency of urination. In patients with IC\/BPS, it was shown that liposomal BoNT-A could also improve bladder pain, but the therapeutic efficacy was not superior to that of the placebo. As the therapeutic mechanisms of BoNT-A include the decreased expression of nerve growth factors, P2X3 receptors, and vanilloid receptors on C-fibers, liposomal BoNT-A might play a more promising role in the treatment of bladder oversensitivity. This article features the contemporary literature regarding BoNT-A, liposomes, and liposomal BoNT-A treatment for functional bladder disorders and potential clinical applications in the future.<\/jats:p>","DOI":"10.3390\/toxins14120838","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T03:03:41Z","timestamp":1669863821000},"page":"838","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-1367","authenticated-orcid":false,"given":"Fan-Ching","family":"Hung","sequence":"first","affiliation":[{"name":"Department of Urology, National Taiwan University Hospital Yunlin Branch, Douliu 64041, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2016.227","article-title":"Functional urological disorders: A sensitized defence response in the bladder-gut-brain axis","volume":"14","author":"Leue","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1464-410X.2008.07573.x","article-title":"Understanding the elements of overactive bladder: Questions raised by the EPIC study","volume":"101","author":"Irwin","year":"2008","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline Amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","article-title":"EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence","volume":"73","author":"Nambiar","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.juro.2012.08.088","article-title":"The prevalence and overlap of interstitial cystitis\/bladder pain syndrome and chronic prostatitis\/chronic pelvic pain syndrome in men: Results of the RAND Interstitial Cystitis Epidemiology male study","volume":"189","author":"Suskind","year":"2013","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2011.03.132","article-title":"Prevalence of symptoms of bladder pain syndrome\/interstitial cystitis among adult females in the United States","volume":"186","author":"Berry","year":"2011","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/nau.20687","article-title":"Status of international consensus on interstitial cystitis\/bladder pain syndrome\/painful bladder syndrome: 2008 snapshot","volume":"28","author":"Hanno","year":"2009","journal-title":"Neurourol. Urodyn."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JU.0000000000002756","article-title":"Diagnosis and Treatment of Interstitial Cystitis\/Bladder Pain Syndrome","volume":"208","author":"Clemens","year":"2022","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature","volume":"183","author":"Anger","year":"2010","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Kuo","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_15","first-page":"e181","article-title":"State of the art in intravesical therapy for lower urinary tract symptoms","volume":"12","author":"Kaufman","year":"2010","journal-title":"Rev. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/mp060001j","article-title":"Recent advances in intravesical drug\/gene delivery","volume":"3","author":"Tyagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","volume":"278","author":"Lewis","year":"2000","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2011.11.001","article-title":"Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain","volume":"12","author":"Dolly","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.urology.2005.02.002","article-title":"Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics","volume":"66","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/nau.22925","article-title":"Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder","volume":"36","author":"Jiang","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrurol.2015.193","article-title":"Current and potential urological applications of botulinum toxin A","volume":"12","author":"Jiang","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1464-410X.2010.09843.x","article-title":"The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis\/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain","volume":"107","author":"Parsons","year":"2011","journal-title":"BJU Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E136","DOI":"10.1111\/j.1464-410X.2010.09911.x","article-title":"Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis\/painful bladder syndrome","volume":"108","author":"Shie","year":"2011","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1464-410X.2009.08675.x","article-title":"Urinary nerve growth factor level is increased in patients with interstitial cystitis\/bladder pain syndrome and decreased in responders to treatment","volume":"104","author":"Liu","year":"2009","journal-title":"BJU Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.11466.x","article-title":"Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis\/bladder pain syndrome","volume":"111","author":"Shie","year":"2013","journal-title":"BJU Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.36076\/ppj.2013\/16\/E15","article-title":"Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome","volume":"16","author":"Kuo","year":"2013","journal-title":"Pain Physician"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.eururo.2006.08.025","article-title":"New frontiers in intravesical therapies and drug delivery","volume":"50","author":"Giannantoni","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/jir.2005.25.627","article-title":"Antifibrogenic effects of liposome-encapsulated IFN-alpha2b cream on skin wounds in a fibrotic rabbit ear model","volume":"25","author":"Lee","year":"2005","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/sj.gt.3302582","article-title":"The structure and composition of liposomes can affect skin regeneration, morphology and growth factor expression in acute wounds","volume":"12","author":"Jeschke","year":"2005","journal-title":"Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0090-4295(02)02281-1","article-title":"Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat","volume":"61","author":"Fraser","year":"2003","journal-title":"Urology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1464-410X.2009.08673.x","article-title":"Instillation of liposomes vs dimethyl sulphoxide or pentosan polysulphate for reducing bladder hyperactivity","volume":"104","author":"Tyagi","year":"2009","journal-title":"BJU Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.juro.2009.06.024","article-title":"Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis\/painful bladder syndrome","volume":"182","author":"Chuang","year":"2009","journal-title":"J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.kjms.2011.06.002","article-title":"Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome","volume":"27","author":"Lee","year":"2011","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s11255-014-0828-5","article-title":"Liposomal bladder instillations for IC\/BPS: An open-label clinical evaluation","volume":"46","author":"Peters","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","article-title":"A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging","volume":"27","author":"Mehnert","year":"2009","journal-title":"World J. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Janicki, J.J., Chancellor, M.B., Kaufman, J., Gruber, M.A., and Chancellor, D.D. (2016). Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. Toxins, 8.","DOI":"10.3390\/toxins8030081"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes","volume":"182","author":"Chuang","year":"2009","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","article-title":"Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats","volume":"172","author":"Chuang","year":"2004","journal-title":"J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: A single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: A prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Liu, H.T., Chen, S.H., Chancellor, M.B., and Kuo, H.C. (2015). Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134803"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis\/Bladder Pain Syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.juro.2009.02.122","article-title":"Clinical phenotyping of women with interstitial cystitis\/painful bladder syndrome: A key to classification and potentially improved management","volume":"182","author":"Nickel","year":"2009","journal-title":"J. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1464-410X.2003.04722.x","article-title":"Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment","volume":"93","author":"Brady","year":"2004","journal-title":"BJU Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2003.12.017","article-title":"P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin","volume":"46","author":"Brady","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_56","first-page":"37","article-title":"Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder","volume":"77","author":"Smet","year":"1997","journal-title":"Lab. Investig."},{"key":"ref_57","first-page":"401M","article-title":"Precision Medicine in Breast Cancer","volume":"88","author":"Odle","year":"2017","journal-title":"Radiol. Technol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/jnnp.57.2.169","article-title":"Intravesical capsaicin for treatment of detrusor hyperreflexia","volume":"57","author":"Fowler","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/01.ju.0000081652.31524.27","article-title":"Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions","volume":"170","author":"Kuo","year":"2003","journal-title":"J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0306-4522(01)00496-1","article-title":"Vanilloid receptor 1 expression in the rat urinary tract","volume":"109","author":"Avelino","year":"2002","journal-title":"Neuroscience"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1464-410x.2001.02190.x","article-title":"Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder","volume":"87","author":"Yiangou","year":"2001","journal-title":"BJU Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1073\/pnas.231243698","article-title":"Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells","volume":"98","author":"Birder","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01181533","article-title":"The structural relations between nerve fibres and muscle cells in the urinary bladder of the rat","volume":"24","author":"Gabella","year":"1995","journal-title":"J. Neurocytol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2003.11.003","article-title":"Management of detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphate release during aging","volume":"63","author":"Yoshida","year":"2004","journal-title":"Urology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-030-20301-6_4","article-title":"Breast Cancer: Current Perspectives on the Disease Status","volume":"1152","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.urology.2008.01.069","article-title":"Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment","volume":"72","author":"Liu","year":"2008","journal-title":"Urology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1464-410X.1997.00097.x","article-title":"Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis","volume":"79","author":"Lowe","year":"1997","journal-title":"Br. J. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: Presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jhang, J.F., and Kuo, H.C. (2021). Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders. Toxins, 13.","DOI":"10.3390\/toxins13050359"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41598-020-80131-5","article-title":"Urine biomarkers in ESSIC type 2 interstitial cystitis\/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm","volume":"11","author":"Jiang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"225.e13","DOI":"10.1016\/j.urology.2012.01.047","article-title":"Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis\/bladder pain syndrome","volume":"80","author":"Liu","year":"2012","journal-title":"Urology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41598-020-80252-x","article-title":"Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment","volume":"11","author":"Yu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","article-title":"Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: An ESSIC proposal","volume":"53","author":"Nordling","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yu, W.R., Jiang, Y.H., Jhang, J.F., and Kuo, H.C. (2022). Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis\/Bladder Pain Syndrome. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051149"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/nau.23141","article-title":"Effects of low energy shock wave therapy on inflammatory moleculars, bladder pain, and bladder function in a rat cystitis model","volume":"36","author":"Wang","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","article-title":"Breast cancer","volume":"365","author":"Veronesi","year":"2005","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kuo, H.C. (2022). Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?. Toxins, 14.","DOI":"10.3390\/toxins14070498"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eururo.2005.12.012","article-title":"Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1468-1331.2011.03618.x","article-title":"Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity","volume":"19","author":"Conte","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0929-6646(10)60008-3","article-title":"Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction","volume":"108","author":"Chen","year":"2009","journal-title":"J. Formos. Med. Assoc."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/12\/838\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:56Z","timestamp":1760146256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/12\/838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":81,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["toxins14120838"],"URL":"https:\/\/doi.org\/10.3390\/toxins14120838","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}